Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights

Abstract

Joel M Mor,1 Alexander C Rokohl,1 Konrad R Koch,1 Ludwig M Heindl1,21Department of Ophthalmology, University of Cologne, Cologne, Germany; 2Center for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Duesseldorf, Ophthalmic Oncology Unit, Cologne, GermanyPurpose: To evaluate the role of sentinel lymph node biopsy (SLNB) in conjunctival melanoma (CM).Methods: This article provides a review of the literature from PUBMED.Results: Data on SLNB in the management of CM are scarce and only two relatively large cohorts have been reported. Although indication criteria for SLNB vary slightly, positive findings can be expected in 11%–13% of CM cases, including small tumors. False negative SLNB findings are rare (<10%). Failure to identify SLNB has been attributed to the surgical learning curve and recurrent tumors with scar tissue impeding spread of the tracer material. Reported 5-year survival rate following CM management including SLNB, is up to 79%, but there are no comparative cohort studies proving the assumed benefit. Adverse events reported were non-severe and transient.Conclusion: Patients can potentially benefit from SLNB and the procedure can be offered to eligible patients. However, there is not enough evidence to support SLNB as a mandatory part of CM management.Keywords: sentinel, biopsy, conjunctival melanoma, lymphatic spread, lymph node

Keywords

• Sentinel – Biopsy – Conjunctival Melanoma – Lymphatic spread – Lymph node